Core Insights - The article compares Concentra Group (CON) and Medpace (MEDP) to determine which stock offers better value for investors [1] - CON has a stronger Zacks Rank of 1 (Strong Buy) compared to MEDP's 3 (Hold), indicating a more favorable earnings outlook for CON [3][7] Valuation Metrics - CON has a forward P/E ratio of 15.59, significantly lower than MEDP's forward P/E of 26.38, suggesting CON is undervalued [5] - The PEG ratio for CON is 2.09, while MEDP's PEG ratio is higher at 3.58, indicating CON's expected earnings growth is more favorable relative to its valuation [5] - CON's P/B ratio stands at 9.44, compared to MEDP's 12.21, further supporting the notion that CON is a better value option [6] Value Grades - Based on various valuation metrics, CON holds a Value grade of B, while MEDP has a Value grade of C, reinforcing CON's position as the superior value stock [6]

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]